Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 9/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027091 | 0.87 | CDK2 (0.54) | CDK2CDK4CDK1CCND1CCNB1 | |
| SCHEMBL3837048 | 0.84 | ALDH1A1 (0.49) | CDK2GAACDK4CDK1CCND1 | |
| SCHEMBL28014547 | 0.77 | GAA (0.47) | CDK2GAACDK4CES2CES1 | |
| SCHEMBL3837825 | 0.76 | LTA4H (0.43) | CDK2CES2CES1MEN1KMT2A | |
| SCHEMBL3840370 | 0.76 | CDK2 (0.48) | CDK2GAACDK4CDK1CCND1 | |
| SCHEMBL4416712 | 0.75 | CDK2 (0.74) | CDK2CDK4CCND1MEN1KMT2A | |
| SCHEMBL4414254 | 0.74 | CDK2 (0.77) | CDK2CDK4CDK1CCND1CCNB1 | |
| SCHEMBL4411192 | 0.73 | CDK2 (0.61) | CDK2CDK4CDK1CCND1MEN1 | |
| SCHEMBL393852 | 0.72 | GABRP (0.50) | GAAMEN1KMT2A | |
| SCHEMBL392559 | 0.72 | IKBKB (0.46) | GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | CDK2 1/4885GAA 3459/4885CDK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.